EHS
EHS

Abrupt bilateral blindness as a rare post-acute demyelinating consequence of COVID-19


Available online 16 June 2022, 100411

eNeurologicalSci
https://doi.org/10.1016/j.ensci.2022.100411Get rights and content

Highlights

COVID-19-related autoimmune condition of central nervous system (CRAD-C) can result in rapidly progressive demyelination.

COVID-19-related demyelination can result in severe long-lasting complications such as persistent blindness.

Timely immunosuppressive treatment could help to prevent CRAD-C severe complications.

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) could prompt various neurological complications. Abrupt visual disturbance was reported in previous reports as a rare severe manifestation of post-coronavirus disease 2019 (COVID-19). Autoimmune conditions were assumed to have an undeniable role in creation of such circumstances. This report presents a 69-year-old woman with sudden bilateral blindness three weeks after recovering from a SARS-CoV-2 infection. Demyelination due to COVID-19-related autoimmune disorder of the central nervous system (CRAD-C) was considered to be the etiology of her bilateral blindness. Due to her progressive demyelination, immunosuppressive treatments were administered, which resulted in stabilizing post-COVID-19 demyelinating lesions. Accordingly, in the case of COVID-19-related neurological deficits, especially the acute and progressive symptoms, there should be great consideration of autoimmune response to prevent serious complications; hence early diagnosis, treatment, and long-term assessment of patients are necessitated.

Keywords

Autoimmunity

Blindness

COVID-19

Demyelination

Post-COVID-19 syndrome

© 2022 Published by Elsevier B.V.



Source link

EHS
Back to top button